| 1 |
Kolb M, Vasakova M. The natural history of progressive fibrosing interstitial lung diseases[J]. Respir Res, 2019, 20(1): 57.
|
| 2 |
Mathai SC, Danoff SK. Management of interstitial lung disease associated with connective tissue disease[J]. BMJ, 2016, 352: h6819.
|
| 3 |
Li J, Bao J, Zeng J, et al. Iguratimod: a valuable remedy from the Asia Pacific region for ameliorating autoimmune diseases and protecting bone physiology[J]. Bone Res, 2019, 7: 27.
|
| 4 |
Li CH, Ma ZZ, Jian LL, et al. Iguratimod inhibits osteoclastogenesis by modulating the RANKL and TNF-alpha signaling pathways[J]. Int Immunopharmacol, 2021, 90: 107219.
|
| 5 |
Yan Q, Du F, Huang X, et al. Prevention of immune nephritis by the small molecular weight immunomodulator iguratimod in MRL/lpr mice[J]. PLoS One, 2014, 9(10): e108273.
|
| 6 |
Wu YX, Sun Y, Ye YP, et al. Iguratimod prevents ovariectomy induced bone loss and suppresses osteoclastogenesis via inhibition of peroxisome proliferator activated receptorγ[J]. Mol Med Rep, 2017, 16(6): 8200-8208.
|
| 7 |
Zhao L, Mu B, Zhou R, et al. Iguratimod ameliorates bleomycin-induced alveolar inflammation and pulmonary fibrosis in mice by suppressing expression of matrix metalloproteinase-9[J]. Int J Rheum Dis, 2019, 22(4): 686-694.
|
| 8 |
Lin H, Wu C, Zhu F, et al. Anti-fibrotic effect of iguratimod on pulmonary fibrosis by inhibiting the fibroblast-to-myofibroblast transition[J]. Adv Med Sci, 2020, 65(2): 338-347.
|
| 9 |
Richeldi L, Collard HR, Jones MG. Idiopathic pulmonary fibrosis[J]．Lancet, 2017, 389(10082): 1941-1952.
|
| 10 |
Nieto MA, Huang RY, Jackson RA, et al. EMT: 2016[J]. Cell, 2016, 166(1): 21-45.
|
| 11 |
Kamitani S, Yamauchi Y, Kawasaki S, et al. Simultaneous stimulation with TGF-β1 and TNF-α induces epithelial mesenchymal transition in bronchial epithelial cells[J]. Int Arch Allergy Immunol, 2011, 155(2): 119-128.
|
| 12 |
Mitchell JP, Carmody RJ. NF-kappa B and the transcriptional control of inflammation[J]. Int Rev Cell Mol Biol, 2018, 335: 41-84.
|
| 13 |
Kim HJ, Litzenburger BC, Cui X, et al. Constitutively active type I insulin-like growth factor receptor causes transformation and xenograft growth of immortalized mammary epithelial cells and is accompanied by an epithelial-to-mesenchymal transition mediated by NF-kappaB and snail[J]. Mol Cell Biol, 2007, 27(8): 3165-3175.
|
| 14 |
Fujimoto H, D′Alessandro-Gabazza CN, Palanki MS, et al. Inhibition of nuclear factor-kappaB in T cells suppresses lung fibrosis[J]. Am J Respir Crit Care Med, 2007, 176(12): 1251-60.
|
| 15 |
Carrington R, Jordan S, Pitchford S C, et al. Use of animal models in IPF research[J]. Pulm Pharmacol Ther, 2018, 51: 73-78.
|
| 16 |
Ashcroft T, Simpson JM, Timbrell V. Simple method of estimating severity of pulmonary fibrosis on a numerical scale[J]. J Clin Pathol, 1988, 41(4): 467-470.
|
| 17 |
Mira-Avendano I, Abril A, Burger CD, et al. Interstitial lung disease and other pulmonary manifestations in connective tissue diseases[J]. Mayo Clin Proc, 2019, 94(2): 309-325.
|
| 18 |
Jiang H, Gao H, Wang Q, et al. Molecular mechanisms and clinical application of Iguratimod: A review[J]. Biomed Pharmacother, 2020, 122: 109704.
|
| 19 |
Heukels P, Moor CC, von der Thüsen JH, et al. Inflammation and immunity in IPF pathogenesis and treatment[J]. Respir Med, 2019, 147: 79-91.
|
| 20 |
Hou J, Ma T, Cao H, et al. TNF-α-induced NF-κB activation promotes myofibroblast differentiation of LR-MSCs and exacerbates bleomycin-induced pulmonary fibrosis[J]. J Cell Physiol, 2018, 233(3): 2409-2419.
|
| 21 |
Pilling D, Vakil V, Cox N, et al. TNF-α-stimulated fibroblasts secrete lumican to promote fibrocyte differentiation[J]. Proc Natl Acad Sci U S A, 2015, 112(38): 11929-11934.
|
| 22 |
Kim KK, Kugler MC, Wolters PJ, et al. Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix[J]. Proc Natl Acad Sci U S A, 2006, 103(35): 13180-13185.
|
| 23 |
Li CW, Xia W, Huo L, et al. Epithelial-mesenchymal transition induced by TNF-α requires NF-κB-mediated transcriptional upregulation of Twist1[J]. Cancer Res, 2012, 72(5): 1290-1300.
|
| 24 |
Markopoulos GS, Roupakia E, Marcu KB, et al. Epigenetic regulation of inflammatory cytokine-induced epithelial-to-mesenchymal cell transition and cancer stem cell generation[J]. Cells, 2019, 8(10): 1143.
|
| 25 |
Wu Y, Deng J, Rychahou PG, et al. Stabilization of snail by NF-kappaB is required for inflammation-induced cell migration and invasion[J]. Cancer Cell, 2009, 15(5): 416-428.
|
| 26 |
Chua HL, Bhat-Nakshatri P, Clare SE, et al. NF-kappaB represses E-cadherin expression and enhances epithelial to mesenchymal transition of mammary epithelial cells: potential involvement of ZEB-1 and ZEB-2[J]. Oncogene, 2007, 26(5): 711-724.
|
| 27 |
Li Y, Zhu G, Zhai H, et al. Simultaneous stimulation with tumor necrosis factor-α and transforming growth factor-β1 induces epithelial-mesenchymal transition in colon cancer cells via the NF-κB pathway[J]. Oncol Lett, 2018, 15(5): 6873-6880.
|